Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)
This grant funds epidemiologic research in the US on new risk factors and their interaction with existing ones in liver cancer development.
Browse similar grants
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: February 5, 2025 (New) | March 5, 2025 (Renewal/Resubmission/Revision)
Funding Amounts: No budget cap; budgets must reflect actual project needs. Maximum project period: 5 years.
Summary: Supports U.S.-focused epidemiologic research on novel and emerging risk factors, and their interplay with established factors, in liver cancer development.
Key Information: Clinical trials are not allowed; applications focused solely on viral hepatitis or cohort infrastructure are non-responsive.
Description
This funding opportunity supports epidemiologic research to advance understanding of the etiology of liver cancer in the United States, with a focus on emerging biological, environmental, and social risk factors and their interaction with established risk factors (such as viral hepatitis). The program encourages studies that address unanswered questions about liver cancer development, including hepatocellular carcinoma and other histological subtypes (e.g., cholangiocarcinoma, hepatoblastoma, angiosarcoma). Projects should aim to inform evidence-based prevention and control strategies and may include aspects of basic or behavioral research if relevant to human mechanisms or targeted prevention.
Research may leverage existing resources (e.g., case-control or cohort studies, biorepositories, databases) and can involve primary or secondary data collection and analysis. Collaboration among U.S. investigators is encouraged, and international collaboration is permitted if directly relevant to U.S. populations.
